New Additions to Drugs.com for 2018
The following 48 drugs were added to the Drugs.com database in 2018.
Ultomiris
Dec 28, 2018 - Ultomiris (ravulizumab-cwvz) is a long-acting C5 complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder (NMOSD).
Motegrity
Dec 19, 2018 - Motegrity (prucalopride) is a selective serotonin type 4 (5‑HT4) receptor agonist for the treatment of chronic idiopathic constipation (CIC) in adults.
Xospata
Nov 28, 2018 - Xospata (gilteritinib) is a kinase inhibitor indicated for the treatment of patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Daurismo
Nov 28, 2018 - Daurismo (glasdegib) is a hedgehog pathway inhibitor indicated for the combination treatment of adult patients ≥75 years with newly-diagnosed acute myeloid leukemia (AML).
Vitrakvi
Nov 27, 2018 - Vitrakvi (larotrectinib) is an oral selective tropomyosin receptor kinase (TRK) inhibitor for the treatment solid tumors harboring NTRK-fusion proteins.
Lorbrena
Nov 19, 2018 - Lorbrena (lorlatinib) is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).
Yupelri
Nov 9, 2018 - Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD).
Bijuva
Oct 30, 2018 - Bijuva (estradiol and progesterone) is a bio-identical hormone combination for the treatment of moderate-to-severe vasomotor symptoms due to menopause.
Xofluza
Oct 25, 2018 -
Talzenna
Oct 17, 2018 - Talzenna (talazoparib) is an oral poly ADP ribose polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
Tegsedi
Oct 9, 2018 - Tegsedi (inotersen) is an antisense oligonucleotide inhibitor of the transthyretin (TTR) protein for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Libtayo
Oct 3, 2018 - Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody
indicated for the treatment of patients with cutaneous squamous
cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer.
Seysara
Oct 2, 2018 - Seysara (sarecycline) is a tetracycline-derived antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Emgality
Oct 1, 2018 - Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine, and for the treatment of episodic cluster headache in adults.
Vizimpro
Sep 28, 2018 - Vizimpro (dacomitinib) is tyrosine kinase inhibitor (TKI) for the treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations.
Copiktra
Sep 25, 2018 - Copiktra (duvelisib) is a first-in-class, oral, dual phosphoinositide-3-kinase (PI3K)-delta/PI3K-gamma inhibitor for the treatment of chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL).
Ajovy
Sep 14, 2018 - Ajovy (fremanezumab-vfrm) is a fully-humanized monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) ligand indicated for the preventive treatment of migraine.
Lumoxiti
Sep 13, 2018 - Lumoxiti (moxetumomab pasudotox-tdfk) is an anti-CD22 recombinant immunotoxin for the treatment of adult patients with hairy cell leukemia.
Delstrigo
Sep 1, 2018 - Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) a nonnucleoside reverse transcriptase inhibitor [NNRTI]) and nucleoside analogue reverse transcriptase inhibitors combination indicated as a complete regimen for the treatment of HIV-1 infection in adults.
Pifeltro
Sep 1, 2018 - Pifeltro (doravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the combination treatment of HIV-1 infection.
Takhzyro
Aug 24, 2018 - Takhzyro (lanadelumab-flyo) is a plasma kallikrein inhibitor (monoclonal antibody) for the prevention of angioedema attacks in patients with hereditary angioedema.
Diacomit
Aug 22, 2018 - Diacomit (stiripentol) is an anticonvulsant indicated for the treatment of seizures associated with Dravet syndrome.
Galafold
Aug 20, 2018 - Galafold (migalastat) is an alpha-galactosidase A (alpha-Gal A) pharmacological
chaperone indicated for the treatment of adults with a confirmed diagnosis of
Fabry disease and an amenable galactosidase alpha gene variant.
Annovera Ring
Aug 16, 2018 - Annovera (ethinyl estradiol and segesterone acetate) is an estrogen and progestin vaginal contraceptive system indicated to prevent pregnancy for up to a year.
Mulpleta
Jul 31, 2018 - Mulpleta (lusutrombopag) is a once-daily, orally administered, thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure.
Orilissa
Jul 31, 2018 - Orilissa (elagolix) is an orally administered gonadotropin-releasing hormone (GnRH) antagonist for the management of moderate to severe pain associated with endometriosis.
Tibsovo
Jul 31, 2018 - Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called the isocitrate dehydrogenase-1 (IDH1) mutation, which can affect your bone marrow. An IDH1 mutation prevents young blood cells from developing into healthy adult blood cells, which can result in blood and bone marrow disorders such as acute myeloid leukemia (AML), myelodysplastic syndromes, or cholangiocarcinoma.
Arakoda
Jul 26, 2018 - Krintafel (tafenoquine) is an 8-aminoquinoline derivative antimalarial for the radical cure (prevention of relapse) of Plasmodium vivax malaria.
Symtuza
Jul 18, 2018 - Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) is a once daily, single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults.
Mektovi
Jun 30, 2018 -
Braftovi
Jun 30, 2018 - Braftovi (encorafenib) is used in the treatment of melanoma, colorectal cancer, or NSCLC with BRAF mutations. Includes Braftovi side effects, interactions, and indications.
Epidiolex
Jun 25, 2018 - Epidiolex (cannabidiol) is a cannabinoid product for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). Dravet syndrome, and tuberous sclerosis complex.
Olumiant
Jun 6, 2018 -
Consensi
Jun 5, 2018 - Consensi (amlodipine and celecoxib) is a calcium channel blocker and nonsteroidal anti-inflammatory drug combination for the treatment of both hypertension and pain associated with osteoarthritis.
Doptelet
May 22, 2018 - Doptelet (avatrombopag) is a second generation orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical procedure, and patients with chronic immune thrombocytopenia.
Aimovig
May 21, 2018 - Aimovig (erenumab-aooe) is a once-monthly, injectable medication that can be self-administered subcutaneously (under the skin) for the prevention of migraine in adults.
Lucemyra
May 17, 2018 - Lucemyra (lofexidine hydrochloride) is a selective alpha 2-adrenergic receptor agonist for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal.
Tavalisse
Apr 18, 2018 - Tavalisse (fostamatinib) is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of patients with chronic immune thrombocytopenia (ITP).
Ilumya
Mar 22, 2018 - Ilumya (tildrakizumab-asmn) is an anti-IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis.
Trogarzo
Mar 14, 2018 - Trogarzo ((ibalizumab-uiyk) is an antiviral medicine that is used in combination with other antiviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults who have received several anti-HIV-1 regimens in the past, and have HIV-1 virus that is resistant to many antiretroviral medicines, and who are failing their current antiretroviral therapy.
Cimduo
Mar 12, 2018 - Cimduo (lamivudine and tenofovir disoproxil fumarate) is a combination of two nucleo(t)side reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Symfi
Mar 12, 2018 - Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Apadaz
Mar 7, 2018 - Apadaz (acetaminophen and benzhydrocodone hydrochloride) is an immediate release combination of acetaminophen and benzhydrocodone, a prodrug of the opioid agonist hydrocodone, indicated for the short-term management of acute pain.
Erleada
Feb 14, 2018 - Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC).
Symdeko
Feb 13, 2018 - Symdeko (ivacaftor/tezacaftor tablets and ivacaftor tablets) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and CFTR corrector combination for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have two copies of the F508del mutation, or who have at least one mutation in the CF gene that is responsive to treatment with Symdeko.
Biktarvy
Feb 7, 2018 - Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) is an integrase strand transfer inhibitor and emtricitabine/tenofovir alafenamide (Descovy) combination for the treatment of HIV-1 infection.
Segluromet
Jan 25, 2018 - Segluromet (ertugliflozin and metformin hydrochloride) is a sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination used to improve glycemic control in adults with type 2 diabetes.
Steglujan
Jan 25, 2018 - Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.